Immunotherapeutic CAR T-Cell Engineering


Creative Commons License

Uzun E. D. , Gacar G. , Yusufoğlu S.

Journal of Immunology and Clinical Microbiology, cilt.4, ss.34-51, 2019 (Diğer Kurumların Hakemli Dergileri)

  • Cilt numarası: 4 Konu: 2
  • Basım Tarihi: 2019
  • Dergi Adı: Journal of Immunology and Clinical Microbiology
  • Sayfa Sayıları: ss.34-51

Özet

Abstract

Cancer is a significant problem in our age and sought alternative therapies. Immunotherapeutic Car T-cell is a different kind of modality treatment under adoptive immunotherapy and has many promising clinical trials in recent years. CARs are synthetic receptors with a modular design. CAR T-cells recognize the antigen by antigen-sensitive antibody header (scFv). In this way, by activating the intracellular signaling pathway, it begins to proliferate and secrete various cytokines to kill the cell they recognize. Research on treating solid tumors with Car T-cell still is a controversial and uncertain issue compared to it frequently uses in cancers of the blood-producing cells (hematologic cancer) such as leukemia and lymphoma. Although engineering immune cells to treat cancer has various side effects such as off-target recognition, neurotoxicity, cytokine release syndrome (CRS) and toxicity, many clinical trial results are optimistic.

Key words: Cancer, Chimeric antigen receptors, CAR T-cell, Immunotherapy, Adoptive cell transfer therapy, Genetic engineering, Toxicity